Skip to main content

Teflaro FDA Approval History

FDA Approved: Yes (First approved October 29, 2010)
Brand name: Teflaro
Generic name: ceftaroline fosamil
Dosage form: Injection
Company: Allergan plc
Treatment for: Pneumonia, Skin and Structure Infection

Teflaro (ceftaroline fosamil) is a cephalosporin antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Development timeline for Teflaro

DateArticle
May 31, 2016Approval Allergan Receives FDA Approval of Teflaro (ceftaroline fosamil) for Pediatric Patients
Nov  1, 2010Approval FDA Approves Teflaro for Bacterial Infections
Sep  8, 2010FDA Advisory Committee Recommends Approval of Forest Laboratories' Ceftaroline Fosamil for the Treatment of Community Acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections

See also

Teflaro (ceftaroline fosamil) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer